β‐Secretase‐1 elevation in transgenic mouse models of Alzheimer’s disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The presence of neuritic plaques is a pathological hallmark of Alzheimer’s disease (AD). However, the origin of extracellular β‐amyloid peptide (Aβ) deposits and the process of plaque development remain poorly understood. The present study attempted to explore plaque pathogenesis by localizing β‐secretase‐1 (BACE1) elevation relative to Aβ accumulation and synaptic/neuritic alterations in the forebrain, using transgenic mice harboring familial AD (FAD) mutations (5XFAD and 2XFAD) as models. In animals with fully developed plaque pathology, locally elevated BACE1 immunoreactivity (IR) coexisted with compact‐like Aβ deposition, with BACE1 IR occurring selectively in dystrophic axons of various neuronal phenotypes or origins (GABAergic, glutamatergic, cholinergic or catecholaminergic). Prior to plaque onset, localized BACE1/Aβ IR occurred at swollen presynaptic terminals and fine axonal processes. These BACE1/Aβ‐containing axonal elements appeared to undergo a continuing process of sprouting/swelling and dystrophy, during which extracellular Aβ IR emerged and accumulated in surrounding extracellular space. These data suggest that BACE1 elevation and associated Aβ overproduction inside the sprouting/dystrophic axonal terminals coincide with the onset and accumulation of extracellular amyloid deposition during the development of neuritic plaques in transgenic models of AD. Our findings appear to be in harmony with an early hypothesis that axonal pathogenesis plays a key or leading role in plaque formation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“BACE1 immunoreactivity was concentrated in a halo surrounding the core of the amyloid deposit, as previously reported [25,85,86].”
In the citing paper
“Our data suggest that BACE1-positive peri-plaque dystrophic neurites are axonal or terminal in origin due to the presence of the predominantly axonal protein neurofilament NF-M [25,74], synaptic vesicle protein synaptophysin (Fig. 6b) [25,85,86] and myelination (Fig. 4), and absence of the somatodendritic protein MAP2 (Fig. 6c) [25,85,86].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 6×
“The 5XFAD and 2XFAD transgenic mouse models have been well characterized (Borchelt et al., 1997; Oakley et al., 2006).”
BackgroundInfluentialBard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · cited 1×
“Plaques were assessed with antibodies to pan-Ab species (3D6, 4G8 and 6E10) and end-specific to Ab40 (Ter-40) and Ab42 (Ter-42) (Bard et al., 2000; Nishitsuji et al., 2007).”
MethodCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · cited 3×
“The present study shows age-dependent elevated BACE1 protein levels and activity in 5XFAD and 2XFAD mouse cortex, consistent with previous reports on transgenic models of AD (Citron et al., 1992; Zhao et al., 2007).”
BackgroundResultBorchelt, D. R., Ratovitski, T., van Lare, J., Lee, M. K., Gonzales, V., Jenkins, N. A., Copeland, N. G., Price, D. L., & Sisodia, S. S. (1997) · Neuron · doi:10.1016/s0896-6273(00)80974-5 · Cited by 1,023
Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
Meyer-Luehmann, M., Spires-Jones, T. L., Prada, C., Garcia-Alloza, M., de Calignon, A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D. M., Bacskai, B. J., & Hyman, B. T. (2008) · Nature · doi:10.1038/nature06616 · Cited by 987 · cited 4×
“shaft diameter (Spires et al., 2005; Meyer-Luehmann et al., 2008; Knafo et al., 2009), whereas axonal dystrophy is characterized by grape-like swelling and rosette-like sprouting (Fiala, 2007).”
BackgroundInfluentialExogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 2×
“It is suggested that plaque formation may begin with small ‘nuclei’ or ‘seeds’ of insoluble Ab fibrils, which develop into overt plaques by attracting available peptides in the area, governed by the fibrillary nature of Ab (Ganowiak et al., 1994; Kane et al., 2000; Walker et al., 2002; Meyer-Luehmann et al., 2006; Eis…”
BackgroundKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease
Garcia-Alloza, M., Robbins, E. M., Zhang-Nunes, S. X., Purcell, S. M., Betensky, R. A., Raju, S., Prada, C., Greenberg, S. M., Bacskai, B. J., & Frosch, M. P. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.08.017 · Cited by 744 · cited 3×
“considered to play a central role in AD pathogenesis by causing synaptic damage, neuritic alteration, glial activation and neuronal death (Garcia-Alloza et al., 2006; Koenigsknecht-Talboo et al., 2008; Meyer-Luehmann et al., 2008; Koffie et al., 2009).”
BackgroundElevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer disease
Yang, L.-B., Lindholm, K., Yan, R., Citron, M., Xia, W., Yang, X.-L., Beach, T., Sue, L., Wong, P., Price, D., et al. (2003) · Nature Medicine · doi:10.1038/nm0103-3 · Cited by 729
Increased expression of the amyloid precursor β‐secretase in Alzheimer's disease
Holsinger, R. M. D., McLean, C. A., Beyreuther, K., Masters, C. L., & Evin, G. (2002) · Annals of Neurology · doi:10.1002/ana.10208 · Cited by 562
Research works printed but not linked: 23
- 10.1016/S0079-6123(04)47025-3 · DOI
- 10.1016/S0014-4886(03)00252-8 · DOI · Paper page
- 10.1038/85064 · DOI · Paper page
- 10.1002/(SICI)1097-4547(19980701)53:1<99::AID-JNR10>3.0.CO;2-Y · DOI
- 10.1007/s00401-007-0284-8 · DOI
- 10.1001/archneur.59.9.1381 · DOI · Paper page
- 10.1006/bbrc.1994.1229 · DOI
- 10.1006/exnr.1997.6739 · DOI
- 10.1002/jnr.21413 · DOI
- 10.1016/j.nbd.2007.06.015 · DOI
- 10.1006/exnr.2000.7598 · DOI
- 10.1002/jnr.1095 · DOI
- 10.1016/j.nbd.2004.10.022 · DOI · Paper page
- 10.1016/j.expneurol.2003.08.018 · DOI · Paper page
- 10.1126/science.1105681 · DOI · Paper page
- 10.1097/00005072-198709000-00006 · DOI
- 10.1002/9780470719749.ch10 · DOI
- 10.1097/00005072-198803000-00006 · DOI
- 10.1007/s00726-001-0113-7 · DOI
- 10.1016/j.neurobiolaging.2006.11.001 · DOI
- 10.1007/s00221-007-0943-y · DOI
- 10.1093/cercor/6.3.524 · DOI
- 10.1002/cne.21239 · DOI
Cited by
Targeting the β secretase BACE1 for Alzheimer's disease therapy
Yan, R., & Vassar, R. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 630
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Vassar, R. (2014) · Alzheimer's Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 410
Gowrishankar, S., Yuan, P., Wu, Y., Schrag, M., Paradise, S., Grutzendler, J., De Camilli, P., & Ferguson, S. M. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1510329112 · Cited by 406
Sadleir, K. R., Kandalepas, P. C., Buggia-Prévot, V., Nicholson, D. A., Thinakaran, G., & Vassar, R. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1558-9 · Cited by 294
Devi, L., & Ohno, M. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.191 · Cited by 282
Metadata
- Authors
- Zhang, X., Cai, Y., Xiong, K., Cai, H., Luo, X., Feng, J., Clough, R. W., Struble, R. G., Patrylo, P. R., & Yan, X.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2009-12
- Volume
- 30
- Issue
- 12
- Pages
- 2271-2283
- ISSN
- 0953-816X
- 1460-9568
- Cited by
- 108
- References
- 22
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: β‐Secretase‐1 elevation in transgenic mouse models of Alzheimer’s disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. https://app.cochat.ai/papers/10.1111/j.1460-9568.2009.07017.x
- The paper
- Zhang, X., Cai, Y., Xiong, K., Cai, H., Luo, X., Feng, J., Clough, R. W., Struble, R. G., Patrylo, P. R., & Yan, X. (2009). β‐Secretase‐1 elevation in transgenic mouse models of Alzheimer’s disease is associated with synaptic/axonal pathology and amyloidogenesis: implications for neuritic plaque development. European Journal of Neuroscience. https://doi.org/10.1111/j.1460-9568.2009.07017.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.